The possible role of candidate receptors in the cellular penetration of HCV from serum of infected patients remains unclear. SR-BI/Cla1 interacts with plasma HDL, native and modified LDL, and VLDL, and facilitates cellular cholesterol efflux to lipoprotein acceptors. SR-BI/Cla1 binds HCV E2 protein and interacts with HCV pseudotypes via the HVR1 of the E2 envelope glycoprotein. Our data reveal that functional SR-BI/Cla1 expressed on the surface of CHO cells mediates the binding and uptake of HCV from the sera of infected patients. Interaction between HCV and SR-BI/Cla1 is not sensitive to either anti-E2 or anti-HVR1 antibodies but is effectively inhibited by anti-βlipoprotein antibodies and competed out by apoB-containing lipoproteins and notably by VLDL. We interpret our data to indicate that VLDL associated with or incorporated into HCV plays a critical role in the primary interaction of HCV with SR-BI/Cla1, whereas the HCV E2 protein does not. In addition, our findings in hepatoma cell lines suggest that the interaction of HCV with human hepatocytes is equally mediated, at least in a part, by VLDL, and as such may represent an alternative pathway for infection. The association of HCV with ApoBcontaining lipoproteins may promote cellular uptake of this virus in the presence of neutralizing antibodies.
new cell culture system based on the cloned HCV of genotype 2, derived from a patient with fulminant hepatitis C, has, however, permitted, for the first time, the production of viral particles (HCVcc), which can infect hepatoma cells in vitro and transmit infection to chimpanzees (2) (3) (4) .
Several cell surface molecules have been proposed as candidate receptors for HCV, including tetraspanin CD81, SR-BI/Cla-1, mannose binding lectins DC-Sign, L-Sign, and heparan sulfate, and the low-density lipoprotein receptor (LDL-R) (5-10). A major role for CD-81 as a receptor for HCVcc particles produced in a cell culture has been reported (2) (3) (4) . However, the role of CD-81 and other candidate receptors in transporting HCV from the serum of infected patients into cells remains to be demonstrated.
Putative flavivirus-like HCV virions, similar to HCVcc, have not yet been purified from HCVinfected patients and characterized. Rather, other unusual forms of HCV have been isolated from patients' sera such as non-enveloped nucleocapsids (11) , lipo-viro particles (12) , and exosomes (13) . Thus, in the absence of purified HCV virions, several surrogate models mimicking putative HCV virions have been used for studies of HCV-cell interactions: E1E2 liposomes (14) , HCVlike baculovirus-derived particles (15, 16) , and viral pseudotypes harboring E1E2 glycoproteins on the surface of the retroviral core (HCVpp) (17, 18) . However, HCV in the serum of infected individuals exhibits highly heterogeneous density profiles and the majority of the circulating virus is associated with β-lipoproteins, i.e., VLDL and LDL (19, 20) . Lipoprotein receptors can thus facilitate the entry of lipoprotein-associated HCV into cells. Indeed, the LDL receptor (LDL-R) internalizes HCV associated with LDL and VLDL in various human cell types in vitro, leading to infection (10, 12, 21) , and only low-density fractions of infectious serum have been shown to transmit infection to chimpanzees (22) and to infect cultured cells in vitro (10, 12, 23) . Considered together, these observations suggest that lipoproteins associated to the virus are critical for the infectivity of serum HCV.
Human SR-BI/Cla1, a candidate receptor for the virus, is an 82 kDa glycoprotein, with cytoplasmic C-and N-terminal domains separated by a large extracellular domain (a.a. 37-439). SR-BI interacts with HDL, VLDL, native and chemically modified LDL (24) , anionic phospholipids (25) , and apoptotic cells (26) . SR-BI/Cla1 can mediate the selective uptake of cholesteryl esters from HDL and LDL (27) , can facilitate the efflux of free cholesterol from cells to lipoprotein acceptors, and can act as an endocytic receptor (28) . The human homologue of SR-BI, i.e., Cla-1, is expressed on hepatic cells, Küpffer cells, sinusoidal endothelial cells, enterocytes, monocytes and macrophages, and cells of the ovary, testis, and adrenal glands (28, 29) . Human SR-BI interacts with recombinant HCV E2 protein (6) and mediates cellular entry of HCVpp expressing E1E2 envelope proteins via the E2 hypervariable domain 1 (HVR1) in the presence of tetraspanin CD-81 as a co-receptor (17) . The capacity of SR-BI/Cla1 to recognize serum HCV and HCVcc has not yet been investigated, and the putative role of this receptor in HCV infection remains to be defined.
We provide evidence that functional SR-BI/Cla1 expressed on the cell surface mediates the binding and cellular uptake of HCV from patients' sera. We equally demonstrate that HCV envelope proteins do not mediate the primary interaction of HCV with SR-BI/Cla1, but it rather depends on virus-associated apo-B-containing lipoproteins, and mainly VLDL. These observations suggest that cell infection in vivo may be mediated by plasma lipoproteins, thereby the binding to hepatoma cell line Huh7 of virus-like particles of the 1a and 1b genotypes produced in insect cells.
Cloning of human SR-BI and generation of SR-BI/Cla1-expressing CHO cell lines
Total RNA was prepared from HepG2 cells, hybridized with random hexamers and reverse transcribed (RT) using M-MLV reverse transcriptase (Invitrogen). The resulting cDNA was subjected to PCR amplification, using PFU turbo DNA polymerase (Stratagene), the sense SR-BI primer 5′-GCCCGGAAGCTTCGCCTGTGTCGTCTCTGT-3′ and the antisense SR-BI primer 5′-TGCAGCATGCATCTTGTGCTCACTCCATTGTTTT-3′ (sequences complementary to SR-BI underlined). The HindIII and SphI sites present at the 5′ end of the sense and antisense primers, respectively (indicated in italic), were used for directional cloning of the PCR product into the HindIII/SphI-digested pDNR-2 plasmid (Clontech). SR-BI cDNA was excised from the resulting construct by digestion with HindIII and PmlI and was inserted between the HindIII and EcoRV sites of pcDNA3.1 (+) (Invitrogen), containing the neomycin resistance gene, to generate the pcDNA-SR-BI expression vector. The SR-BI sequence (nucleotides +57 to +1953) in the final construct was verified by DNA sequencing. We generated stable cell lines expressing SR-BI by transfecting CHO-K1 cells with pcDNA-SR-BI using Lipofectin (Invitrogen).
Free cholesterol efflux studies
Stably transfected cell clones and parental cells were used to seed 96-well plates (6000 cells/well) and were incubated for 24 h in complete F12 medium supplemented with 10% (V/V) FCS and 2 µg/ml ACAT inhibitor (CP113,818). The medium was then replaced with complete F12 medium supplemented with 3 µCi/ml [3H]cholesterol, 20% (V/V) FCS and 2 µg/ml ACAT inhibitor. Cells were incubated for 24 h, and the cell monolayer was washed once with 1% BSA/F12 and once with F12. Cholesterol efflux was stimulated by adding 100 µl of serum-free medium containing purified lipoproteins (VLDL, LDL, or HDL) at a final concentration of 50 µg protein/ml. Cells were incubated for 2 h, and the medium was then removed and filtered through Multiscreen (Millipore) filtration plates with 0.45 µm pores. The cells were washed, and cell lipids were extracted with 100 µl isopropyl alcohol.
[3H]Cholesterol content in the medium and in the total cell lipid extract was measured by liquid scintillation counting. For cholesterol efflux studies performed in the presence of antiserum directed against human SR-BI the cells were first incubated with various concentrations of whole rabbit antiserum (or control anti-sera) for 30 min before the efflux period.
Serum samples
Serum samples were obtained from volunteer blood donors with normal alanine transaminase (ALT) levels and from chronic HCV carriers. All serum samples tested positive for anti-HCV antibodies by MONOLISA anti-HCV PLUS (Bio-Rad, Marnes la Coquette, France) and RIBA (ORTHO Diagnostics) and for HCV-RNA by b-DNA (Chiron). Plasma samples were stored frozen at -80°C. Viral load in serum samples was quantified by b-DNA technology (Bayer Diagnostics).
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Binding and uptake of natural HCV into SR-BI/Cla1-expressing cells Confluent monolayers of CHO cells were grown for 48 h in six-well tissue culture plates to obtain ~10 6 cells per well. Cells were washed twice with F12 medium without FCS and antibiotics and left in 1 ml F12 for the assay. We then added 50 µl of HCV-positive serum to each well, which was incubated for 2 h at 37°C. All assays were performed at least in triplicate. At the end of the incubation period, unbound HCV was removed by washing with F12 and total RNA extracted as described below. The quantity of HCV RNA associated with CHO cells expressing SR-BI/CLA1 was compared with control CHO cells using the non-parametric MannWhitney U test. Data were analyzed separately for each series of experiments. P values less than 0.05 were considered significant. All calculations were performed using Stata 8.0, statistical software (Stata Corporation, College Station, TX).
Virus internalization was investigated by incubating cells with HCV-positive serum for 2 h at 4, 14, or 37°C. The cells were then washed, and HCV RNA associated with the cells was quantified by RT-PCR. We also investigated the effect of lysosomotropic agents, such as ammonium chloride (NH 4 Cl), and amantadine on HCV/SR-BI interaction. Before inoculation with HCV-positive serum, cells were incubated for 30 min at 37°C with 500 µl of F12 medium containing an inhibitor. Cells were then incubated with HCV-positive serum for 2 h at 37°C and the amount of HCV RNA associated with cells was then determined as described above.
In parallel, after inoculation with infectious sera, cells were washed and incubated with 70-700 μM suramin (Sigma) in PBS for 1h at 4°C. The cells were then washed and HCV RNA quantified by RT-PCR. In control experiments, HCV-positive sera were incubated with cells in the presence of the same concentrations of suramin.
Quantitative real-time RT-PCR
After the cells had been incubated with the virus, total RNA was extracted by adding 1 ml RNAble (Eurobio) and 100 µl CHCl 3 per well. The aqueous phase was collected and extracted with CHCl 3 . RNA in the aqueous phase was then precipitated with isopropanol, washed with 70% ethanol and dissolved in 20 µl DEPC-treated water and stored at -20°C. Quantitative realtime RT-PCR was used to detect and quantify HCV-RNA associated with cells. We used the following primers for HCV-RNA amplification: 5′-TGCGGAACCGGTGAGTACA-3′ and 5′-CGGGTTGATCCAAGAAAGGA-3′, together with the internal probe 5′FAM-CGGAATTGCCAGGACGACCGG-3′TAMRA. The results were normalized by simultaneous quantification of the cellular hypoxanthine-guanine-phosphoribosyltransferase RNA (HPRT-RNA) with primers 5′-CCAACACTTCGAGAGGTCCTTT-3′ and 5′-GTTGAGGACATAATTGACACTGGTAAA-3′ and the internal probe 5′VIC-CTTGCAACCTTAACCATT-3′MGB. Reverse-transcription, amplification and real-time detection of PCR products were performed with 5 µl total RNA samples, using an AbiPrism 7700 and the one-step Reverse Transcriptase qPCR Master Mix from Eurogentec (RT-QPRT-032X). The cycle number at which fluorescence began to increase and crossed the threshold depended on the initial number of target copies and was defined as the threshold cycle. HCV RNA was quantified by comparison with a reference serum, standardized using the HCV RNA quantification panel from AcroMetrix (Berkeley, CA) and expressed in international units (IU).
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Inhibition of HCV/SR-B/Cla1 interaction by anti-SR-BI antibodies
Transfected and parental CHO cells were incubated for 30 min with serial dilutions of rabbit SR-BI/Cla1 antiserum. We then added 50 µl of HCV-positive serum to the cells and incubated for 2 h at 37°C. The cells were washed, total RNA was extracted and HCV-RNA quantified by RT-PCR. Results are expressed in IU of HCV-RNA. An irrelevant rabbit serum was used as a control.
Inhibition of HCV/SR-B/Cla1 interaction by anti-envelope antibodies
HCV-positive serum samples (50 µl) were incubated with HCV-IG or normal human IgG for 1 h at 37°C. In parallel, HCV-positive serum samples were incubated with mice sera containing anti-HVR1 antibodies (or pre-immune mice sera) for 1 h at 37°C. The serum samples were then incubated with cells for 2 h at 37°C, as described above. Results are expressed in IU of HCV RNA bound to cells in the presence or absence of antibodies.
Inhibition of HCV/SR-B/Cla1 interaction by lipoproteins and β lipoprotein antibodies
CHO and CHO-SR-BI cells were incubated for 15 min with various concentrations of human VLDL, LDL, or HDL. HCV-positive serum samples were then added and incubated with cells for 2 h at 37°C. The effect of purified lipoproteins on the interaction of HCV with SR-BI was also investigated, using lipoproteins as competing ligands. In these experiments, lipoproteins were added to cells simultaneously with HCV-positive serum, and the cells were then incubated for 2 h at 37°C.
HCV-positive serum samples were incubated with serial dilutions of antibodies directed against human β-lipoproteins, anti-ApoA1, anti-ApoB, or anti-ApoE antibodies or irrelevant sera and then with cells for 2 h at 37°C. Results were expressed in IU of HCV RNA in the presence or absence of antibodies.
Immunofluorescence microscopy
We investigated the cellular expression of SR-BI/Cla1 by washing transfected and nontransfected CHO cells in PBS, fixing them with 4% paraformaldehyde (PFA) in PBS and quenching with 50 mM NH 4 Cl. Cells were then incubated for 1 h at room temperature with rabbit antibodies directed against SR-BI/Cla1, washed, and bound primary antibody was detected with Alexa 488-labeled goat anti-rabbit IgG (Molecular Probes). Cells were washed, mounted in Vectashield mounting medium (Vector Laboratories, UK) and examined either by confocal laser (Leica TCS4D) or by fluorescence microscopy (Zeiss Axiovert 200M).
We determined whether the SR-BI/Cla1 expressed on CHO cells was functional by incubating cells with AcLDL labeled with Alexa 594 (Molecular Probes), at a concentration of 10 µg/ml, for 30 min at 4°C. Cells were then washed and incubated for another hour at 37°C. Cell association of DiI-labeled HDL to parental and SR-BI-expressing CHO cells was performed by incubating cells grown on coverslips with DiI-HDL (20 µg/ml) in serum-free medium for 15 min at 37°C. After incubation, cells were washed and fixed with 2% formaldehyde in PBS for 10 min at room temperature. The cells were counterstained for nuclei with 4', 6-diamidino-2- phenylindole dihydrochloride (DAPI) (Molecular Probes) and examined by fluorescence microscopy.
The binding capacity of recombinant E2 protein to transfected and non-transfected cells was analyzed by incubating cells for 2 h at room temperature with 1 μg of E2/ml. Fixation and quenching were then performed as described above. Mab P33, kindly provided by Dr. A Patel (University of Glasgow), was used to detect E2 protein bound to cells and revealed with antimouse IgG labeled with Alexa 488.
Inhibition experiments on HepG2 and Huh7 cells
Inhibition experiments, using HepG2 and Huh7 cells and anti-SR-BI antibodies, HCV-IG, plasma lipoproteins, and anti-lipoprotein antibodies, were performed by using the same reagents and under similar conditions as for CHO-SR-BI cells.
FACScan analysis
Cells (10 6 ), untreated or treated with lysosomotropic agents, were washed with PBS, detached with Versene (Invitrogen), and saturated with 1% BSA in PBS. Cells were then incubated with rabbit antiserum directed against human SR-BI for 30 min at 4°C followed by goat anti-rabbit antibody coupled to Alexa 488 (Molecular Probes). Cells were then fixed by incubation with 1% paraformaldehyde and analyzed with the Facscalibur system (Beckton Dickinson).
RESULTS
SR-BI/Cla1 expressed at the plasma membrane of transfected CHO cells is fully functional
Expression of SR-BI/Cla1 on the surface of transfected cells was assessed by immunofluorescence confocal microscopy ( Fig. 1A-C) . Transfected cell clones bound and internalized AcLDL, a highly specific ligand for scavenger receptors including SR-BI (Fig. 1D-F) . HDL binding to SR-BI-expressing CHO cells was equally enhanced as compared with CHO cells (Fig. 1G, H) . Such binding was totally inhibited by the addition of anti-SR-BI antibodies (data not shown). Binding of E2 protein by transfected but not by parental CHO cells was also evidenced (Fig. 1I, J) .
Transfected cell clones displayed significantly higher levels of [3H]cholesterol efflux in the presence of HDL (Fig. 2) , LDL, and VLDL (not shown), as compared with control, nontransfected CHO cells. Pre-incubation of SR-BI-transfected cell clones with anti-SR-BI antibodies resulted in abrogation of SR-BI-mediated cholesterol efflux to all classes of lipoprotein acceptors; the basal cholesterol efflux activity of parental CHO cells in the presence of lipoprotein acceptors was not affected. These studies showed that SR-BI/Cla1 expressed on transfected CHO cells was fully functional in facilitating cellular cholesterol efflux to a wide range of acceptors.
Natural HCV interacts with SR-BI/Cla1 on transfected cells
We investigated the capacity of natural HCV to interact with SR-BI/Cla1 by incubating serum samples from asymptomatic or symptomatic HCV carriers (genotype 1a or 1b) with transfected or parental CHO cells (as a control) and subsequently determined the amount of HCV genomic material associated with cells by quantitative real-time RT-PCR. Significantly larger amounts (2-to 15-fold) of HCV RNA were found associated with transfected CHO cells as compared with control parental CHO cells in 9 out of 10 serum samples analyzed; 8 were derived from asymptomatic and 2 from symptomatic HCV carriers. Viral load in these sera ranged from 22,104 to 3,918,280 IU/ml, as determined by b-DNA assay. The amount of HCV RNA bound by transfected cells was not directly correlated with viral load in serum. These results indicate that the nature of viral particles rather than viral load influenced the interaction of HCV with SR-BI/Cla1.
The amount of HCV RNA associated with cells increased in direct relation to the volume of HCV-positive serum added and the amount of cell associated HCV RNA increased with the period of incubation, up to 8 h (data not shown).
Anti-SR-BI antibodies inhibit the interaction of HCV with SR-BI-CHO cells
We used anti-SR-BI antibodies to inhibit HCV/cell interaction and, thereby, to confirm that the interaction of HCV with transfected CHO cells was mediated by SR-BI/Cla1. A rabbit antiserum directed against the extracellular domain of human SR-BI that inhibited cholesterol efflux via SR-BI (Fig. 2) effectively blocked the interaction of HCV with transfected cells in a dosedependent manner (Fig. 3) . Normal rabbit serum used as a control at the same concentrations had no effect on virus-cell interaction. Thus, the SR-BI/Cla1 expressed on transfected cells mediated the binding of authentic HCV from the sera of infected patients to theses cells.
HCV is internalized into the cell via SR-BI/Cla1
We then investigated whether the binding of HCV to transfected CHO cells led to uptake of the virus. The quantity of HCV-RNA associated with transfected cells at 37°C was markedly superior than at 4 or at 14°C, suggesting that SR-BI/Cla1-mediated HCV trafficking into the cell occurred by energy-dependent mechanisms (Fig. 4A) . Moreover, lysosomotropic agents such as NH 4 Cl (Fig. 4B) and amantadine (Fig. 4C) , which raise luminal pH (used in optimal, non-toxic concentrations (32), led to decrease in the amount of HCV-RNA associated with transfected cells in a dose-dependent manner. These agents did not decrease SR-BI/Cla1 expression on the cell surface, thus quantification of SR-BI/Cla1 by FacScan demonstrated that the number of SR-BI-positive cells increased by 26% in the presence of 90 mM NH 4 Cl and by 10% in the presence of 4.5 mM amantadine. These findings support the contention that the acidification of endosomes is critical to cellular uptake of natural HCV into via SR-BI/Cla1.
Suramin is known to dissociate lipoproteins from their receptors, therefore, treatment of cells with suramin after inoculation with infectious sera should remove the virus bound to the cell surface. As shown in Fig. 4D , most of the HCV RNA (80%) remained associated with transfected cells after suramin treatment, consistent with their internalization. In control experiments, pre-incubation of HCV positive sera with 10-fold lower concentrations of suramin caused complete inhibition of virus/cell interaction. Considered together these findings indicated that serum HCV was taken up into the cell via SR-BI.
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HCV/SR-BI/Cla1 interaction is not mediated by the E2 protein
We then evaluated whether the interaction between natural HCV and SR-BI/Cla1 occurred directly, via the HCV envelope, or indirectly, via plasma lipoproteins. We attempted to inhibit the HCV/SR-BI interaction using well-defined antibodies. HCV-IG, containing large amounts of anti-E1 and anti-E2 antibodies, which neutralized the infection of liver cells with HCVpp in vitro (33), did not inhibit the interaction of natural HCV with SR-BI/Cla1-expressing cells (Fig. 5A) . Mouse polyclonal antibodies which reacted with a large number of HVR1 peptides and blocked the binding of virus-like particles of genotypes 1a and 1b to hepatic cells (S. Viazov personal communication) also did not interfere with virus/cell interaction (Fig. 5B) . Thus, HCV from the sera of infected patients did not recognize SR-BI/Cla1 via the HVR1 domain or other regions of the HCV E2 glycoprotein.
HCV/SR-B/Cla1 interaction is mediated by apoB-containing lipoproteins
We further investigated the mechanism of interaction of natural HCV with SR-BI/Cla1 by evaluating the influence of authentic SR-BI/Cla1 ligands (HDL, LDL and VLDL). Transfected and non-transfected CHO cells were incubated with each lipoprotein class and then with HCVpositive sera. VLDL inhibited virus/cell interaction efficiently (by up to 80%), whereas LDL had a much less pronounced effect (up to 40% inhibition at maximal concentrations) (Fig. 5C ). Similar results were obtained when purified lipoproteins were added at the same time as the HCV-positive serum (data not shown). By contrast, HDL had no effect when used as an "inhibitor" or "competitor". Virus/cell interaction was however inhibited efficiently, and in a dose-dependent manner by anti-βlipoprotein antibodies (Fig. 5D ). These antibodies were reactive with LDL, VLDL, and ApoB, but non-reactive with HDL, ApoA1, and ApoA2, as evidenced by direct ELISA.
HCV interaction with SR-BI/Cla1 was not inhibited by anti-ApoA1 and anti-ApoB, whereas anti-ApoE antibodies led to app. 30% inhibition of virus cell interaction (data not shown). Thus, ApoB does not appear to be directly involved in HCV binding to transfected cells. Since anti-SR-BI antibodies inhibited HCV interaction with CHO-SR-BI cells by 80% and VLDL was better inhibitor than LDL these observations ruled out the potential role of hamster LDL-R on CHO cells. Overall these observations support the contention that serum HCV interacted with SR-BI/Cla1 via ApoB containing lipoproteins, mainly VLDL.
Natural HCV binds to hepatic cells via ApoB-containing lipoproteins
We validated our findings for CHO-SR-BI cells by using the hepatoma cell lines: HepG2 and Huh7. The HepG2 cell line exhibits similar properties to human hepatocytes (34) and is permissive for HCV replication (35) . Furthermore, HepG2 cells express SR-BI/Cla1 and also LDL-receptor on their surface and are fully competent for binding to HCV E2 protein via SR-BI/Cla1 (6). These cells do not, however, express CD-81, which mediated in vitro infection of hepatoma cells with HCVcc (2-4) and HCVpp (36) . The HepG2 cells efficiently bound serum HCV and prior incubation of these cells with anti-SR-BI/Cla1 antibodies decreased the amount of HCV RNA associated with cells by ~40% (Fig. 6A) , showing that interaction of natural HCV is mediated at least in part by SR-BI/Cla1. As in the CHO-SR-BI model, HCV-IG did not inhibit the interaction of natural virus with hepatic cells (Fig. 6B) . VLDL strongly inhibited the interaction of HCV with hepatic cells, whereas HDL and LDL had little or no effect (Fig. 6C) . Finally, prior incubation of HCV-positive sera with anti-βlipoprotein antibodies led to marked inhibition of HCV/cell interaction, in a dose-dependent manner (Fig. 6D) . These results were confirmed using several serum samples as a source of the virus and the Huh7 hepatoma cell line, which expresses CD-81 in addition to LDL-R and SR-BI /Cla1 (data not shown).
These findings confirmed that SR-BI on hepatic cells interacted with HCV from patients' sera. In addition they indicate that interaction of natural virus with human hepatocytes is at least in a part mediated by SR-BI and dependent on ApoB-containing lipoproteins, and in particular on VLDL.
DISCUSSION
We provide the first direct demonstration that human SR-BI/Cla1 mediates the binding to cells of natural HCV from the serum of infected individuals and its subsequent cellular uptake. We equally provide evidence that serum HCV does not recognize SR-BI/Cla1 directly, via the E2 envelope glycoprotein. Rather, our data suggest that VLDL either incorporated or associated to the virus particles plays a critical role in the primary interaction of the virus with SR-BI at the cell surface.
Human hepatocytes, the main target cells for HCV, express other HCV receptor molecules in addition to SR-BI/Cla1, and these include CD-81 and LDL-R. To investigate the mechanism of interaction of natural HCV with SR-BI/Cla1, we, therefore, developed an experimental model, based on the stable transfection of a non-permissive CHO cell line cell with a cDNA encoding SR-BI/Cla1. As HCV cannot be detected in the serum by immunological methods, we assessed the capacity of natural HCV to interact with cells expressing functional receptors by means of quantitative real-time RT-PCR.
Our analyses of the cellular efflux of free cholesterol, binding, and internalization of AcLDL, the interaction of SR-BI/Cla1with specific ligands such as HDL, LDL, VLDL, and the capacity to bind HCV E2 protein demonstrated that SR-BI/Cla1 expressed on transfected CHO cells was fully functional. Thus, SR-BI/Cla1 mediated the binding and cellular uptake of natural HCV in the absence of CD-81, which was required for infection with both HCVpp (17) and HCVcc (4). Indeed, HCV/SR-BI interaction was energy-dependent. Moreover, the inhibitory effects of two lysosomotropic agents suggested that lysosome acidification-dependent cellular trafficking is involved in HCV uptake via SR-BI/Cla1. In addition, control experiments involving suramin treatment demonstrated that a majority of the virus was internalized into the cell via SR-BI. The key role of SR-BI/Cla1 in this process was confirmed by inhibiting virus/cell interaction with antibody directed against the extracellular domain of the receptor; this antibody equally interfered with SR-BI/Cla1-mediated free cholesterol efflux to all lipoprotein classes and with HDL binding to the receptor.
Serum HCV did not interact with SR-BI via the E2 envelope glycoprotein. Indeed, human anti-E2 antibodies, derived from patients' sera and which blocked the infection of human hepatoma cell lines with HCVpp (33) did not affect the interaction of natural HCV with SR-BI/Cla1. Polyclonal anti-HVR1 antibodies that were broadly reactive with synthetic peptides corresponding to HVR1 regions and inhibited the binding of virus-like particles of the 1a and 1b genotypes to hepatic cells equally had no effect on the interaction between HCV and SR-BI/Cla1. Thus, the mechanism by which serum HCV interacts with SR-BI/Cla1 differs from those proposed for HCVpp. Unlike HCVpp, HCV circulating in the serum does not recognize SR-BI/Cla1via the HVR1 domain or other regions of the E2 protein. Notably, HCV lacking the HVR1 region is infectious in chimpanzees, which is compatible with the suggestion that the major mechanism(s) of HCV cell entry in vivo do not involve the HVR1 domain of E2 protein (37) . It remains also unclear as to whether the E2 protein and HCV envelope in general are accessible on HCV circulating in the serum since detection of HCV envelope proteins in most HCV-positive sera remains difficult (13).
In our study, serum HCV competed with plasma-derived Apo-B-containing lipoproteins, primarily VLDL, for binding to SR-BI/Cla1. HDL had no effect on this interaction, although HDL particles increased the number of HCVpp taken up via SR-BI (18) . Studies with SR-BI mutants have elucidated mechanism(s) of interaction of SR-BI/Cla1 with its multiple ligands. Indeed, SR-BI binds HDL, VLDL, and LDL, with high affinity, independently and by different mechanisms (24) . Moreover, independent sites located in the extracellular domain of the receptor are responsible for the interaction of SR-BI with its various ligands. As VLDL were the most efficient inhibitors of the interaction between HCV and SR-BI/Cla1, and antibodies directed against βlipoproteins inhibited this interaction, we interpret these findings to indicate that VLDL associated with the virus mediated the interaction of HCV with SR-BI/Cla1.
In contrast to HCVpp and HCVcc, HCV circulating patients' sera is heterogeneous in nature and associated with lipoprotein particles (19, 20) and mainly VLDL (20) ; indeed only low-density HCV could transmit infection to chimpanzees (38) and to various cell types in vitro (10, 23) . These investigations suggested that lipoproteins associated to the virus are critical for infectivity of serum HCV. As neither the E1E2 envelope proteins (14) nor HCVpp (18, 39) interact directly with LDL, HDL, or VLDL, it is probable that HCV and VLDL associate during viral assembly in the hepatocyte ER-the compartment containing nascent VLDL (40) .
All the key findings obtained in our experimental system (CHO-SR-BI/Cla1) correlate well with data obtained using the human heptocarcinoma cell lines HepG2 and Huh7. Notably, HepG2 cells do not express CD-81, which mediated the in vitro infection of hepatoma cells with HCVcc (2-4) and was required for cell infection with HCVpp (36) . Partial inhibition of HCV/cell interaction by anti-SR-BI antibodies revealed that SR-BI/Cla1 mediated the interaction of HCV with its target cell, although clearly SR-BI/Cla1 was not the only HCV receptor molecule on human hepatocytes. Either anti-HVR1 or anti-E2 antibodies did not inhibit the interaction of serum HCV with its target cell. Instead, VLDL and anti-βlipoprotein antibodies efficiently inhibited this interaction. Our findings suggest the existence of an alternative mechanism for the interaction of natural virus with human hepatocytes-distinct from that mediated by E2 envelope protein and CD-81-but depending upon VLDL and SR-BI. Nonetheless, we cannot exclude the possibility that E1 and E2 envelope proteins might play a role in later stages of HCV uptake or, alternatively, in HCV morphogenesis and exit from the cell (41) , in which CD-81 may act as an "exit receptor" for HCV (13) .
Lipoproteins associated to virus particles can mask neutralizing epitopes, thereby facilitating mechanisms that lead to viral escape from the humoral immune response. Lipoproteins associated to the virus might also enable HCV to infect its target cells in the presence of neutralizing antibodies. Indeed, our in vitro observations are consistent with a relative inefficiency of anti-envelope antibodies coexisting with infectious HCV in patients' sera and in vaccinating approaches. Our data correlate, however, with other clinical observations: thus, chronic HCV infection is characterized by low LDL cholesterol levels (42, 43) , whereas abnormally high triglyceride levels have been detected in patients who have recovered from acute HCV infection (Marzouk et al. Metabolic liver disease and HCV infection in rural Egypt. Submitted). It is conceivable that free lipoprotein particles can compete with lipoproteinassociated HCV for binding to lipoprotein receptors, thereby facilitating the clearance of HCV in these patients. Indeed, VLDL and LDL have been shown to compete with serum HCV for the LDL-R (10, 12, 21) and, in our study, for binding to SR-BI/Cla1. Further understanding of the impact of lipoproteins associated to HCV on viral infectivity and of the mechanisms by which HCV-lipoprotein complexes interact with lipoprotein receptors could have key implications for future therapeutic approaches targeting to inhibit HCV infection. 
